A new report from the National Audit Office has found that In 2017-18, 42% (87 of 207) of Clinical Commissioning Groups (CCGs) were rated either ‘requires improvement’ or ‘inadequate’, with as little as 10% rated as ‘outstanding’.Original Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.